Cytosorbents’ (CTSO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Thursday,Benzinga reports. The firm currently has a $1.00 target price on the medical research company’s stock. HC Wainwright also issued estimates for Cytosorbents’ FY2028 earnings at ($0.07) EPS and FY2029 earnings at ($0.05) EPS.

Other equities research analysts also recently issued research reports about the company. StockNews.com assumed coverage on Cytosorbents in a report on Thursday. They issued a “hold” rating for the company. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO opened at $0.97 on Thursday. The company has a market capitalization of $53.04 million, a price-to-earnings ratio of -2.69 and a beta of 0.78. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The firm has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. On average, equities research analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Skylands Capital LLC increased its position in Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after buying an additional 26,195 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Cytosorbents in the fourth quarter worth $30,000. Northern Trust Corp lifted its position in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents during the 4th quarter worth about $99,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.